Kraig Biocraft Laboratories Announces Commencement of Full Operations at Second Production Rearing Center in Southeast Asia
1. KBLB's second production rearing center in Southeast Asia is operational.
2. Two facilities ensure continuous rearing cycles of recombinant spider silk silkworms.
3. New genetic lines are introduced, enhancing production efficiencies.
4. The upgrade aims to avoid bottlenecks experienced in the past.
5. This expansion positions KBLB to meet growing market demand.
The operational rearing center enhances KBLB's growth potential, reminiscent of past expansions leading to higher stock prices. Historical integrations often result in strong market performances, indicating this move could similarly bolster investor confidence and stock valuation.
How important is it?
The article highlights KBLB's operational capabilities and strategic expansions, crucial for transitioning to profitability. Increased production capacity is vital for scaling and maintaining competitive advantage in their market.
Why Long Term?
The facility and process improvements are expected to yield benefits over several quarters. Similar expansions in biotech and production often take time to reflect in stock prices as markets adjust.
ANN ARBOR, Mich., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that its second production rearing center in Southeast Asia is now fully operational.
With two active production facilities, Kraig Labs has established parallel operations designed to ensure continuous rearing cycles of its specialized recombinant spider silk silkworms. This dual-site capacity increases resilience and scalability, providing greater material output consistency, as Kraig Labs advances its commercialization strategy.
Teams are now active at both rearing centers, working with the Company's established parental lines for BAM-1 production hybrids, as well as three additional parental lines introduced earlier this summer. These new genetic lines represent a significant expansion of the Company's breeding program and are expected to further enhance production efficiencies.
These facilities are designed to create efficient redundancy to avoid bottlenecks the Company experienced in the past. This is a major leap forward in terms of creating sustained production.
"Becoming fully operational at our second rearing center is a milestone that strengthens the foundation of our spider silk production platform," said Kim Thompson, founder and CEO of Kraig Labs. "Having parallel operations allows us to maintain continuous rearing cycles, diversify our breeding program, and accelerate the development of next-generation hybrids. This expanded capacity is essential as we push forward in scaling production and bringing our recombinant spider silk to market."
The opening of this second rearing facility reflects the Company's ongoing commitment to building a robust, reliable, and scalable spider silk production system in Southeast Asia, positioning Kraig Labs to meet growing demand from diverse markets and industries.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com